ヨーロッパの全エクソームシーケンシング市場 – 業界動向と2029年までの予測

市場分析と洞察

ヨーロッパの全エクソームシーケンシング市場は、2022年から2029年の予測期間に市場の成長が見込まれています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に16.0％のCAGRで成長すると分析しています。がんなどのさまざまな慢性疾患の予測、治療、モニタリングのための次世代シーケンシング法の採用の増加は、予測期間における市場の需要を推進する主な原動力です。

しかし、全エクソームシーケンシングの技術に関連する法的問題や治療に関連する副作用は、全エクソームシーケンシング市場の将来の成長を妨げる可能性があります。主要な市場プレーヤーによるパートナーシップや買収などの戦略的提携の採用は、全エクソームシーケンシング市場の成長の機会として機能します。

全エクソームシークエンシング市場の定義

全エクソームは、ゲノム内の遺伝子のタンパク質コード領域全体を配列するゲノム技術です。全エクソーム配列決定は、複数の病状の統一的な診断を求めている患者が利用できます。個人のゲノムのエクソン（またはタンパク質コード）領域と関連配列のヌクレオチド配列を主に決定するために使用される実験室プロセスで、完全な DNA 配列の約 1% を占め、WES とも呼ばれます。全エクソーム配列決定は、ゲノムのタンパク質コード領域の配列決定を伴う、広く使用されている全エクソーム配列決定方法です。ヒトのエクソームはゲノムの 2% 未満を占めますが、既知の疾患関連変異の約 85% を含むため、この方法は全ゲノム配列決定のコスト効率に優れた代替手段となります。

エクソームエンリッチメントを使用したエクソームシーケンシングは、集団遺伝学、遺伝病、がん研究など、幅広いアプリケーションにわたってコーディングバリアントを効率的に検出できます。世界的な全エクソームシーケンシング市場の成長は、シーケンシングの時間とコストの削減に起因しています。新しい技術とがん治療法の開発により、臨床腫瘍学における全エクソームシーケンシング市場は今後数年間で大きな可能性を秘めています。

ヨーロッパ全エクソームシークエンシング市場の動向

ドライバー

• 次世代シーケンシング（NGS）の採用の増加

ゲノミクスに焦点を当てた薬理学がさまざまな慢性疾患、特に癌の治療において大きな役割を果たし続けるにつれて、次世代シーケンシング (NGS) は、個々の腫瘍や特定の受容体の分子基盤に対するより深く正確な洞察を提供する強力なツールとして進化しています。

NGS は従来の方法に比べて精度、感度、速度の面で優れており、腫瘍学の分野に大きな影響を与える可能性があります。NGS では 1 回のアッセイで複数の遺伝子を評価できるため、原因となる変異を特定するために複数のテストを注文する必要がなくなります。

• 標的シーケンシング法の利用増加

ゲノミクスに焦点を当てた薬理学がさまざまな慢性疾患、特に癌の治療において大きな役割を果たし続けるにつれて、次世代シーケンシング (NGS) は、個々の腫瘍や特定の受容体の分子基盤に対するより深く正確な洞察を提供する強力なツールとして進化しています。

NGS は従来の方法に比べて精度、感度、速度の面で優れており、腫瘍学の分野に大きな影響を与える可能性があります。NGS では 1 回のアッセイで複数の遺伝子を評価できるため、原因となる変異を特定するために複数のテストを注文する必要がなくなります。

拘束

• エクソンの網羅性が低い

すべてのエクソンが包括的に捕捉されているわけではありません。重要なエクソンは、ヒトゲノムの現在の標準注釈には含まれていない可能性があり、現在の WES 技術でエクソンの 100% をカバーするのは困難です。その結果、これらの「見逃された」エクソン内の疾患を引き起こす変異は検出されません。

WESは構造変異に対する感度が低いため、検出範囲が限られています。それでも、インデルや重複を含む一部のCNVはWESで検出できますが、技術的な制限により、他のCNVは見逃される可能性があります。

Opportunity

• Strategic Initiatives by the key market player

The demand for whole exome sequencing is increasing in the market owing to the increased incidence of genetic disease along with increased geriatric population across the region. Thus, the top market players have implemented the strategy of collaboration with other market players aimed at improving business operations and profitability.

Challenge

• Ethical and legal issues related to whole exome sequencing

Rapid advances in high throughput genomic technologies and next generation sequencing are making medical genomic research more readily accessible and affordable, including the sequencing of patient and control whole genomes and exomes in order to elucidate genetic factors underlying disease. Progress of high throughput genomic technologies and next generation sequencing (NGS) methods in recent years has changed the scope of human genomic studies. These advances have made it feasible to routinely perform whole exome sequencing (WES) studies.

Due to the large-scale, collaborative nature of studies, ethical and legal issues are of increasing concern and have important implications in Africa. African populations are of unique interest because, despite having the highest levels of genetic diversity, living in a vast array of environmental and cultural settings, as well as suffering from a high burden of disease that could be studied using genomics approaches, they are facing legal issues in WES.

Post COVID-19 Impact on Whole Exome Sequencing Market

COVID-19 has resulted in a substantial upsurge in demand for medical supplies from both healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to have a big impact on the whole exome sequencing market.

Recent Development

• In May, 2022, Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally. This has helped the company to expand its presence.
• In March, 2022, several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA seeks to educate healthcare providers and other stakeholders about the value of such testing to assure adherence to existing guidelines from professional medical societies, to inform medical management and cascade testing, and to improve clinical outcomes. This has helped company to adhere to guidelines.

Europe Whole Exome Sequencing Market Segmentation

Europe whole exome sequencing market is segmented on the basis of component, product and service, application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Component

• Second-Generation Sequencing
• Third-Generation Sequencing

On the basis of component, the Europe whole exome sequencing market is segmented into second-generation sequencing and third-generation sequencing.

Product and Services

• Systems
• Kits
• Services

On the basis of product and service, the Europe whole exome sequencing market is segmented into systems, kits and services.

Application

• Diagnostics
• Drug Discovery and Development
• Personalized Medicine
• Agriculture & Animal Research
• Others

On the basis of application, the Europe whole exome sequencing market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.

End User

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Clinical Laboratories
• Others

On the basis of end user, the Europe whole exome sequencing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinics, clinical laboratories and others.

Distribution Channel

• Direct Trade
• Retail sales
• Others

On the basis of distribution channel, the Europe whole exome sequencing market is segmented into direct trade, retail sales and others.

Whole Exome Sequencing Market Country Level Analysis

The whole exome sequencing market is analyzed and market size information is provided by component, product and service, application, end user and distribution channel.

The countries covered in the whole exome sequencing market report are Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Belgium and Rest of Europe.

Germany is expected to grow due to rapidly declining costs of sequencing, strategic alliances among major companies and research institutes.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Whole exome sequencing market also provides you with detailed market analysis for every country growth in healthcare industry. Moreover, it provides detailed information regarding healthcare services and treatments, impact of regulatory scenarios, and trending parameters regarding whole exome sequencing market.

Competitive Landscape and Whole Exome Sequencing Market Share Analysis

Whole exome sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to whole exome sequencing market.

The major companies which are dealing in the  whole exome sequencing market are Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc., among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-Pacific vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

SKU-68567